Close Menu

NEW YORK, May 21 - Cambridge Antibody Technology will partner with Immunex to jointly discover and develop new antibody-based drugs for treating inflammation, the companies said Monday. 

The agreement calls for Immunex to provide two undisclosed protein drug targets and for CAT to develop antibodies to those targets using its antibody phage display and screening technologies. Immunex is to bear responsibility for pre-clinical evaluation, clinical trials, and product commercialization. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.